Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells In Vitro

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1727-1733

  Shen, Y ^a   Wang, X ^a   Xia, W ^a   Wang, C ^a   Cai, M ^a   Xie, H ^a   Zhou, L ^a   Zheng, S ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CARCINOMA; PRIORITY JOURNAL;

CELL DIVISION; CELL LINE, TUMOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PANCREATIC NEOPLASMS; PROPYLENE GLYCOLS; SIROLIMUS; SPHINGOSINE;

EID: 45749146180     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.150     Document Type: Article

References (16)

1. Lutz J., and Heemann U. Tumors after kidney transplantation. Curr Opin Urol 13 (2003) 105
2. Stracke S., Ramudo L., Keller F., et al. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc 38 (2006) 766
3. Eisen H.J., Tuzcu E.M., Dorent R., et al. RAD B253 Study Group: Rapamycin for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847
4. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270
5. Ho J.W., Man K., Sun C.K., et al. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4 (2005) 1430
6. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252
7. Azuma H., Takahara S., Ichimaru N., et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62 (2002) 1410
8. Azuma H., Takahara S., Horie S., et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol 169 (2003) 2372
9. Sonoda Y., Yamamoto D., Sakura S., et al. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 281 (2001) 282
10. Shen Y., Cai M., Xia W., et al. FTY720, a synthetic compound from Isaria sinclairii. Cancer Lett 254 (2007) 288
11. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680
12. Grewe M., Gansauge F., Schmid R.M., et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 59 (1999) 3581
13. Huang S., and Houghton P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Invest Drugs 3 (2002) 295
14. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252
15. MacDonald A., Scarola J., Burke J.T., et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22 Suppl B (2000) B101
16. Budde K., Schmouder R.L., Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13 (2002) 1073